literature

SARS_CoV_2 mutation literature information.

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene.

PMID: 34796036 2021 Immune network

Introduction: A single point mutation A701V presents in the S2 region that is distinct from SARS-CoV-2 alpha variant.

Table: A701V

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.

PMID: 34722330 2021 Frontiers in cellular and infection microbiology

Result: In contrast, T716I, A570D, D118H and A701V mutations caused a modest reduction in viral infectivity.

Figure: The S protein of N501Y.V1 include nine mutations (HV69-70 del, 144 del, N501Y, D614G, P681H, T716I, S982A, and D1118H<

Discussion: Pseudovirion with HV69-70 deletion could enhance the infectivity of the virus, while single-site mutation T716I, A570D, D118H, and A701V caused a modest reduction in viral infectivity.

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.

PMID: 34931200 2021 medRxiv

Introduction: The Beta variant contained spike mutations L18F, D80A, D215G, Delta242-244, R246I, K417N, E484K, N501Y and A701V.

Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants.

PMID: 34880635 2021 Infection and drug resistance

Table: A701V

Molecular Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 Isolates From Central Inner Sardinia.

PMID: 35095827 2021 Frontiers in microbiology

Table: p.Ala701Val

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.

PMID: 34956222 2021 Frontiers in immunology

Table: A701V

Hotspot Mutations in SARS-CoV-2.

PMID: 34912372 2021 Frontiers in genetics

Introduction: In December 2020, the variant B.1.351 was first detected in South Africa, with mutations such as K417N, E484K, N501Y, D614G, and A701V.

Introduction: The Brazilian variant P.1 also has almost the same mutations as the B.1.351 variant, but instead of A701V, the P.1 variant has H555Y mutation.

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection.

PMID: 34923570 2021 Cell discovery

Method: pS-B.1.1.7 and pS-B.1.351 plasmids were constructed with mutant S genes expressing the spike protein of the B.1.1.7 variant (GenBank: QQH18545.1, containing the H69, V70, and Y145 deletions and N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations) and B.1.351 variant (GenBank: QRI43207.1, containing the L242, A243, and L244 deletions and L18F, D80A, D215G, S305T, K417N, E484K, N501Y, D614G

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.

PMID: 34925381 2021 Frontiers in immunology

Introduction: The Beta (B.1.351) variant encodes an S protein with nine mutations (L18F, D80A, D215G, Del 241-243, K417N, E484K, N501Y, D614G and A701V, three of which (K417N, E484K and N501Y) are in the RBD.

Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern.

PMID: 33925854 2021 Microorganisms

Result: The SA-VOC has seven aa substitutions in the S-protein, including D80A, D215G, K417N, E484K, N501Y, D614G, and A701V, and three aa 'LLA' are deleted between positions 241-243.

Browser Board

Co-occurred Entities

Filtrator